Skip to main content
Clinical Trials/NCT01560026
NCT01560026
Unknown
Not Applicable

Study for Elevate the Feasibility of Ovarian Preservation With Endometrial Carcinoma

Taipei Veterans General Hospital, Taiwan1 site in 1 country300 target enrollmentAugust 2000

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Endometrial Cancer
Sponsor
Taipei Veterans General Hospital, Taiwan
Enrollment
300
Locations
1
Primary Endpoint
from the time of diagnosis to the time of disease recurrence or last follow time
Last Updated
14 years ago

Overview

Brief Summary

Endometrial cancer is one of the most common female malignancies in the United States, and has increased in incidence in Taiwan in recent decades.A recent population-based analysis noted that 4% of endometrial cancers occurred in women aged 40 years or younger, furthermore it is up to 15% in Taiwan according to the data of cancer registry. The standard treatment of endometrial cancer results in surgical menopause and places patients at risk for the long-term sequelae of estrogen deprivation. The goal of this study was to determine the frequency of a coexisting ovarian malignancy and to evaluate the outcome of ovarian preservation in women with treatment for endometrial cancer.

Detailed Description

we reviewed the cases with early stage of endometrial cancer who have primary staging surgery between January 1989 to December 2009. The enrolled patients will be divided into two group (oophorectomy vs. ovary preservation) for analysis:the outcome and recurrence type.To evaluate the outcome of ovarian preservation in women with endometrial cancer .

Registry
clinicaltrials.gov
Start Date
August 2000
End Date
December 2012
Last Updated
14 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

vghtpe user

Director

Taipei Veterans General Hospital, Taiwan

Eligibility Criteria

Inclusion Criteria

  • early stage endometrial cancer after primary surgery exclusion criteria:
  • MMMT, type 2 endometrial cancer

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

from the time of diagnosis to the time of disease recurrence or last follow time

Time Frame: disease recurrence or last follow time, up to one year

the time of diagnosis to the time of disease recurrence or last follow time

Study Sites (1)

Loading locations...

Similar Trials